Associated Papers
Germline heterozygous SH2B3 p.Glu78Lys variant: a three-patient case series with myeloproliferative neoplasms.
Iaquinta G et al.
Experimental Hematology, 2026
SH2B3 (Lnk) Mutations in Myeloid Neoplasms: Morphologic Spectrum, Co-Mutation Patterns, and Clinical Correlates.
Tefferi A et al.
American Journal of Hematology, 2025
The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders.
Maslah N et al.
Leukemia, 2017
LNK mutations and myeloproliferative disorders.
McMullin MF et al.
American Journal of Hematology, 2016
12q24 locus association with type 1 diabetes: SH2B3 or ATXN2?
Auburger G et al.
World Journal of Diabetes, 2014
Role of the adaptor protein LNK in normal and malignant hematopoiesis.
Gery S et al.
Oncogene, 2013
SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F.
Koren-Michowitz M et al.
British Journal of Haematology, 2013
The Lnk adaptor protein: a key regulator of normal and pathological hematopoiesis.
Velazquez L
Archivum Immunologiae Et Therapiae Experimentalis, 2012
LNK can also be mutated outside PH and SH2 domains in myeloproliferative neoplasms with and without V617FJAK2 mutation.
Hurtado C et al.
Leukemia Research, 2011
[Classification for myeloproliferative neoplasms and function of novel mutations].
Kirito K
[rinsho Ketsueki] the Japanese Journal of Clinical Hematology, 2011
New mutations and pathogenesis of myeloproliferative neoplasms.
Vainchenker W et al.
Blood, 2011
LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations.
Pardanani A et al.
Leukemia, 2010
LNK mutations in JAK2 mutation-negative erythrocytosis.
Lasho TL et al.
The New England Journal of Medicine, 2010
Select a paper to view details